Hemogenyx Pharmaceuticals PLC Appointment of Business Advisor & Board Observer (3656G)
26 July 2021 - 4:00PM
UK Regulatory
TIDMHEMO
RNS Number : 3656G
Hemogenyx Pharmaceuticals PLC
26 July 2021
26 July 2021
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Appointment of Business Advisor & Board Observer
Dr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned
business leader brings industry experience in corporate and private
venture capital, business development, R&D and general
management.
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments for blood diseases,
announces the appointment of Dr Alan E. Walts as a Board observer
and business advisor.
Dr Walts is a US-based Venture Partner with Advent Life
Sciences, a position he has held since January 2014. Dr Walts
currently serves as a Director and audit committee member at Eloxx
Pharmaceuticals (NASDAQ: ELOX), and as Executive Chairman of Artax
Biopharma and PIC Therapeutics. He is also a founder, Director and
Treasurer of The Termeer Foundation, a public 501(c)(3)
organization founded in 2019. Dr Walts is currently an independent
Director of Neuroelectrics Corp, and a business advisor and board
observer of several private companies including Amylyx
Pharmaceuticals, Arrakis Therapeutics, and Alpha Anomeric. Dr
Walts' previous board and business advisory experience includes X4
Pharmaceuticals, Aura Biosciences, and Arrakis Therapeutics. Dr
Walts has over 25 years of industry experience at Genzyme in
business development, business strategy, research and development,
general management, and venture capital. Prior to leaving Genzyme
in 2013, Dr. Walts most recently managed Genzyme's corporate
venture fund, Genzyme Ventures (now Sanofi Ventures). Following
Genzyme's landmark sale to Sanofi, he served as a business advisor
to founding Chairman and CEO of Genzyme Henri Termeer from
2013-2017, and worked closely with Henri on founding and investing
in early-stage companies.
Dr Walts received a Ph.D. in chemistry from MIT in 1985, carried
out post-doctoral research in biochemistry at MIT with Professor
Christopher Walsh, and completed the executive Program for
Management Development at Harvard Business School.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx
Pharmaceuticals, commented:
"We are excited to welcome Dr Alan Walts as business advisor and
Board observer. Alan's rich experience and deep insight into the
biopharmaceutical industry will undoubtedly help to accelerate
Hemogenyx Pharmaceuticals' significant development pipeline."
Dr Alan Walts commented:
"I am excited about the potential of Hemogenyx Pharmaceuticals'
technology and I look forward to working with Dr Sandler and the
board of Hemogenyx Pharmaceuticals."
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New
York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to treat blood and
autoimmune disease and to bring the curative power of bone marrow
transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary
product candidates, as well as platform technologies that it uses
as engines for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. The Company's technology
has the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPPPURCMUPGGQA
(END) Dow Jones Newswires
July 26, 2021 02:00 ET (06:00 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024